Claes Ginman

1.8k total citations · 1 hit paper
25 papers, 1.2k citations indexed

About

Claes Ginman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hepatology. According to data from OpenAlex, Claes Ginman has authored 25 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 5 papers in Hepatology. Recurrent topics in Claes Ginman's work include Prostate Cancer Treatment and Research (16 papers), Prostate Cancer Diagnosis and Treatment (11 papers) and Cancer Treatment and Pharmacology (6 papers). Claes Ginman is often cited by papers focused on Prostate Cancer Treatment and Research (16 papers), Prostate Cancer Diagnosis and Treatment (11 papers) and Cancer Treatment and Pharmacology (6 papers). Claes Ginman collaborates with scholars based in Sweden, Finland and Denmark. Claes Ginman's co-authors include Camilla Thellenberg‐Karlsson, Lars Franzén, M. Seke, Anders Widmark, Adalsteinn Gunnlaugsson, Jon Kindblom, Elisabeth Kjellén, Bengt Johansson, Kirsten Björnlinger and Morten Høyer and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Claes Ginman

23 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

2019 559 citations Anders Widmark, Adalsteinn Gunnlaugsson et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claes Ginman Sweden	15	839	438	259	185	170	25	1.2k
Scott C. Morgan Canada	19	1.2k 1.4×	389 0.9×	337 1.3×	305 1.6×	308 1.8×	100	1.7k
Christopher J. DiBlasio United States	18	1.4k 1.6×	108 0.2×	97 0.4×	247 1.3×	397 2.3×	30	1.7k
Paul Van Cangh Belgium	13	1.5k 1.7×	352 0.8×	111 0.4×	158 0.9×	418 2.5×	34	2.0k
A. Wygoda Poland	13	301 0.4×	106 0.2×	118 0.5×	180 1.0×	145 0.9×	55	664
Ching‐Yeh Hsiung Taiwan	17	621 0.7×	183 0.4×	198 0.8×	355 1.9×	319 1.9×	21	1.1k
A. Verbaeys Belgium	12	1.8k 2.1×	637 1.5×	228 0.9×	118 0.6×	300 1.8×	36	1.9k
Carolyn F. Wilson Canada	12	143 0.2×	79 0.2×	59 0.2×	322 1.7×	376 2.2×	25	670
Renée Bultijnck Belgium	10	875 1.0×	212 0.5×	428 1.7×	262 1.4×	228 1.3×	29	1.1k
Douglas Adamson United Kingdom	16	123 0.1×	32 0.1×	75 0.3×	276 1.5×	190 1.1×	40	853
Ben E.E.M. van den Borne Netherlands	16	529 0.6×	20 0.0×	48 0.2×	247 1.3×	206 1.2×	29	977

Countries citing papers authored by Claes Ginman

Since Specialization

Citations

This map shows the geographic impact of Claes Ginman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claes Ginman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claes Ginman more than expected).

Fields of papers citing papers by Claes Ginman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claes Ginman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claes Ginman. The network helps show where Claes Ginman may publish in the future.

Co-authorship network of co-authors of Claes Ginman

This figure shows the co-authorship network connecting the top 25 collaborators of Claes Ginman. A scholar is included among the top collaborators of Claes Ginman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claes Ginman. Claes Ginman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nilsson, P., Adalsteinn Gunnlaugsson, L. Beckman, et al.. (2026). Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial. The Lancet Oncology. 27(3). 293–301.

Nilsson, Per, Adalsteinn Gunnlaugsson, L. Beckman, et al.. (2025). 4981 Ultra-hypofractionated radiotherapy for localised prostate cancer: 10-year outcomes of the HYPO-RT-PC phase 3 trial (ISRCTN45905321). Radiotherapy and Oncology. 206. S4414–S4415. 1 indexed citations

Hjälm-Eriksson, Marie, et al.. (2021). Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study. Anticancer Research. 42(1). 87–92. 1 indexed citations

Fransson, Per, Per Nilsson, Adalsteinn Gunnlaugsson, et al.. (2021). Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. The Lancet Oncology. 22(2). 235–245. 93 indexed citations

Ginman, Claes, et al.. (2019). Effects of a nutrition intervention on acute and late bowel symptoms and health-related quality of life up to 24 months post radiotherapy in patients with prostate cancer: a multicentre randomised controlled trial. Supportive Care in Cancer. 28(7). 3331–3342. 14 indexed citations

Widmark, Anders, Adalsteinn Gunnlaugsson, L. Beckman, et al.. (2019). Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. The Lancet. 394(10196). 385–395. 559 indexed citations breakdown →

Kellokumpu‐Lehtinen, Pirkko‐Liisa, Marie Hjälm-Eriksson, Camilla Thellenberg‐Karlsson, et al.. (2019). Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial. European Urology. 76(6). 823–830. 21 indexed citations

Hjälm-Eriksson, Marie, Lennart Åström, Timo Marttila, et al.. (2018). A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial.. Journal of Clinical Oncology. 36(15_suppl). 5000–5000. 7 indexed citations

Widmark, Anders, Adalsteinn Gunnlaugsson, L. Beckman, et al.. (2018). OC-0599: Ultrahypofractionation for prostate cancer: Outcome from the Scandinavian phase 3 HYPO-RT-PC trial. Radiotherapy and Oncology. 127. S314–S314. 14 indexed citations

10.

Kellokumpu‐Lehtinen, Pirkko‐Liisa, Ulrika Harmenberg, Timo Joensuu, et al.. (2013). 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. The Lancet Oncology. 14(2). 117–124. 135 indexed citations

11.

Hjälm-Eriksson, Marie, Camilla Thellenberg‐Karlsson, Lennart Åström, et al.. (2012). Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial. Prostate Cancer and Prostatic Diseases. 15(3). 303–307. 21 indexed citations

12.

Kellokumpu‐Lehtinen, Pirkko, Camilla Thellenberg‐Karlsson, Lennart Åström, et al.. (2011). High toxicity in patients receiving adjuvant docetaxel plus hormone treatment after radical radiotherapy for high-risk prostate cancer: A preplanned safety report of SPCG 13 trial.. Journal of Clinical Oncology. 29(7_suppl). 63–63. 2 indexed citations

13.

Fosså, Sophie D., Anne-Birgitte Jacobsen, Claes Ginman, et al.. (2007). Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study. European Urology. 52(6). 1691–1699. 41 indexed citations

14.

Hardell, Lennart, Swen‐Olof Andersson, Michael Carlberg, et al.. (2006). Adipose Tissue Concentrations of Persistent Organic Pollutants and the Risk of Prostate Cancer. Journal of Occupational and Environmental Medicine. 48(7). 700–707. 71 indexed citations

15.

Nilsson, Sten, Peter Strang, Claes Ginman, et al.. (2005). Palliation of Bone Pain in Prostate Cancer Using Chemotherapy and Strontium-89. A Randomized Phase II Study. Journal of Pain and Symptom Management. 29(4). 352–357. 25 indexed citations

16.

Kälkner, Karl‐Mikael, Claes Ginman, Sten Nilsson, et al.. (1997). Positron emission tomography (PET) with 11C-5-hydroxytryptophan (5-HTP) in patients with metastatic hormone-refractory prostatic adenocarcinoma. Nuclear Medicine and Biology. 24(4). 319–325. 17 indexed citations

17.

Nilsson, S., Claes Ginman, Håkan Åhlström, et al.. (1995). 11C-methionine positron emission tomography in the management of prostatic carcinoma. 8(1). 23–38. 7 indexed citations

18.

Påhlman, Lars, et al.. (1985). Preoperative Irradiation of Primarily Non-Resectable Adenocarcinoma of the Rectum and Rectosigmoid. Acta Radiologica Oncology. 24(1). 35–39. 24 indexed citations

19.

Ginman, Claes, Per Hartvig, P. Jakobsson, et al.. (1982). Clinical Evaluation of Oral Methadone in Treatment of Cancer Pain. Acta Anaesthesiologica Scandinavica. 26(s74). 124–127. 15 indexed citations

20.

Säwe, Juliette, et al.. (1981). Patient-controlled dose regimen of methadone for chronic cancer pain.. BMJ. 282(6266). 771–773. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact